Katja Pokrovskaja Tamm

Katja Pokrovskaja Tamm

Auto-generated profile, based on publicly available information

Katja Pokrovskaja Tamm

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2002 in Oncogene
Verified
Journal Article
Closed access
LTLena Thyrell
Lena Thyrell
SESven Erickson
Sven Erickson
BZBoris Zhivotovsky
Boris Zhivotovsky
KPKatja Pokrovskaja
Katja Pokrovskaja
OSOlle Sangfelt
Olle Sangfelt
DGDan Grandér
Dan Grandér

24 April 2009 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
ELE Laane
E Laane
KTK Pokrovskaja Tamm
K Pokrovskaja Tamm
EBE Buentke
E Buentke
KIK Ito
K Ito
PKP Khahariza
P Khahariza
DGD Grandér
D Grandér

1 November 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Theocharis PanaretakisTheocharis Panaretakis
Theocharis Panaretakis
KPKatja Pokrovskaja
Katja Pokrovskaja
MSMaria C. Shoshan
Maria C. Shoshan
DGDan Grandér
Dan Grandér
The anthracyclin doxorubicin (DXR) is a major antitumor agent known to cause cellular damage via a number of mechanisms including free radical formation and inhibition of topoisomerase II. It is not clear, however, how the subsequent lesions may lead to the apoptotic death of the cell. We have here examined the effects of DXR on activation of pro-apoptotic members of the Bcl-2 family, all of which are connected to the mitochondrial events of apoptosis. In two human cell lines (lymphoma and myeloma), clinically relevant concentrations of DXR were found to induce apoptosis, first observed after 24 h of treatment. Apoptosis correlated with modulation of Bak and Bax to their active conformations. bax- as well as bak-deficient mouse embryo fibroblasts were resistant to DXR compared with wild-type mouse embryo fibroblasts further supporting a role for these proteins as main DXR-induced apoptosis regulators. Furthermore, using immunocytochemistry as well as chemical blocking of putative apical pathways we could demonstrate that Bak is activated prior to Bax. In the human cell lines, DXR was furthermore found to induce high protein levels of Bik, another BH3-only protein. DXR-induced apoptosis was completely blocked in Bcl-2-overexpressing U266 cells. Interestingly, in Bcl-2-transfected cells Bak activation was also blocked, while Bax was still partially active in agreement with differential regulation of these two proteins. Furthermore, co-incubation of the phosphatidylinositol 3-kinase (PI3K)-inhibitor LY294002 potentiated the apoptotic response to DXR. This enhanced apoptosis was preceded by enhanced Bak and Bax activation, and both responses as well as apoptosis were blocked in transfectants overexpressing Bcl-2. In summary, several pieces of evidence suggest that DXR induces apoptosis through a sequential and differential activation of Bak and Bax.

9 January 2017 in Nature Medicine
Verified
Journal Article
Closed access
Nikolas HeroldNikolas Herold
Nikolas Herold
SRSean Rudd
Sean Rudd
LLLinda Ljungblad
Linda Ljungblad
KSKumar Sanjiv
Kumar Sanjiv
IMIda Hed Myrberg
Ida Hed Myrberg
TSTorsten Schaller
Torsten Schaller

1 October 2018 in Cancer Letters
Verified
Journal Article
Open access
MDMatheus Dyczynski
Matheus Dyczynski
YYYasmin Yu
Yasmin Yu
MOMagdalena Otrocka
Magdalena Otrocka
SPSantiago Parpal
Santiago Parpal
TBTiago Braga
Tiago Braga
KTKatja Pokrovskaja Tamm
Katja Pokrovskaja Tamm
Resistance to chemotherapy is a challenging problem for treatment of cancer patients and autophagy has been shown to mediate development of resistance. In this study we systematically screened a library of 306 known anti-cancer drugs for their ability to induce autophagy using a cell-based assay. 114 of the drugs were classified as autophagy inducers; for 16 drugs, the cytotoxicity was potentiated by siRNA-mediated knock-down of Atg7 and Vps34. These drugs were further evaluated in breast cancer cell lines for autophagy induction, and two tyrosine kinase inhibitors, Sunitinib and Erlotinib, were selected for further studies. For the pharmacological inhibition of autophagy, we have characterized here a novel highly potent selective inhibitor of Vps34, SB02024. SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo. Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer.

1 June 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LTLena Thyrell
Lena Thyrell
LHLinn Hjortsberg
Linn Hjortsberg
VAVelmurugesan Arulampalam
Velmurugesan Arulampalam
Theocharis PanaretakisTheocharis Panaretakis
Theocharis Panaretakis
SUSabine Uhles
Sabine Uhles
KPKatja Pokrovskaja
Katja Pokrovskaja
Interferon (IFN) α induces a caspase-dependent apoptosis that is associated with activation of the proapoptotic Bak and Bax, loss of mitochondrial membrane potential, and release of cytochrome c. In addition to the onset of the classical Jak-STAT pathway, IFNα also induced phosphoinositide 3-kinase (PI3K) activity. Pharmacological inhibition of PI3K activity by Ly294002 disrupted IFN-induced apoptosis upstream of mitochondria. Inhibition of mTOR by rapamycin or by overexpression of a kinase dead mutant of mTOR, efficiently blocked IFNα-induced apoptosis. A PI3K and mTOR-dependent phosphorylation of p70S6 kinase and 4E-BP1 repressor was induced by IFNα treatment of cells and was strongly inhibited by Ly294002 or rapamycin. The activation of Jak-STAT signaling upon IFNα stimulation was not affected by abrogating PI3K/mTOR pathway. Neither was the expression of several IFNα target genes affected, nor the ability of IFNα to protect against virus-induced cell death affected by inhibition of the PI3K/mTOR pathway. These data demonstrate that an intact PI3K/mTOR pathway is necessary for the ability of IFNα to induce apoptosis, whereas activation of the Jak-STAT pathway alone appears to be insufficient for this specific IFNα-induced effect.